ECE2018 Oral Communications Thyroid from basics to clinics (5 abstracts)
Identification of an epigenetic biomarker panel for predicting the development of distant metastases in differentiated thyroid cancer
Helena Rodríguez 1 , Carles Zafon 2, , Núria Villalmanzo 1 , Lorena Cerda 1 , Carmela Iglesias 5, , Jordi Real 1 , Joan Gil 1 , Esther N. Klein Hesselink 6 , Bettien M. van Hemel 7 , Cristina Montero-Conde 8 , Jordi L. Reverter 9, , Dídac Mauricio 9, , Manel Puig-Domingo 9, , Mercedes Robledo 8, , Thera P. Links 6 & Mireia Jordà 1,
1Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain; 2Diabetes and Metabolism Research Unit (VHIR) and Department of Endocrinology, University Hospital Vall d’Hebron and Autonomous University of Barcelona, Barcelona, Spain; 3Consortium for the Study of Thyroid Cancer (CECaT), Barcelona, Spain; 4Biomedical Research Networking Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Institute of Health Carlos III (ISCIII), Madrid, Spain; 5Department of Pathology, Vall D’Hebron Universtiy Hospital, Barcelona, Spain; 6Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; 7Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; 8Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; 9Department of Endocrinology and Nutrition, Germans Trias i Pujol Research Institute and University Hospital, Barcelona, Spain; 10Biomedical Research Networking Center in Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain.
Background: Differentiated thyroid cancer (DTC) is usually associated with an excellent prognosis. The main cause of death is due to distant metastases, but distant metastatic DTC (dmDTC) presents an interpatient heterogeneity. Some patients with distant metastases live with stable disease for many years, while others die very early. Still no effective biomarkers are available to predict either which patients will eventually develop distant metastases or what will be the final outcome of patients with dmDTC. The key for the future development of predictors probably lies in a better understanding of the (epi)genetic wiring of dmDTC. DNA methylation, one of the most studied epigenetic mechanism, affects CpG sites and is associated with transcriptional repression. While major progress has been made in understanding DNA methylation in DTC, the epigenetic architecture of dmDTC is completely unknown.
Objective: The aim of this study was to characterize the DNA methylomes of dmDTC and to identify biomarkers that predict the development of distant metastases.
Methods: We profiled DNA methylation of a series of 98 formalin-fixed paraffin-embedded tissues including 30 low risk non-metastatic DTC, 35 dmDTC, 18 metastases and 15 adjacent normal tissues using the Illumina Infinium HumanMethylationEPIC platform. We selected candidate biomarkers using the Simple Logistics classifier implemented in RWeka, and validated them by bisulfite-PCR-sequencing, bisulfite pyrosequencing and MethylQuant.
Results: We identified a signature of 156 CpGs associated with dmDTC independently of histology and mutations in BRAF and RAS. DNA methylation differed between distant metastatic (synchronous and metachronous) and low-risk non-metastatic primary tumors, while the paired primary tumor and distant metastases were similar, suggesting that molecular alterations of the primary tumors may dictate the ability to metastasize. The signature was enriched in hypomethylations and over half were located in promoters and enhancers, pointing out their role in the regulation of gene expression. We selected 10 independent CpGs with high classification power, and quantified DNA methylation by different techniques to develop a simplified quantitative and cheap assay implementable in the routine clinical practice. Based on preliminary results MethylQuant analysis appeared as the best alternative for on its simplicity, performance and cost-effectiveness.
Conclusion: We identified a 10-epigenetic biomarker panel associated with distant metastases in thyroid cancer and established new quantitative DNA methylation assays.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more